HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance

Non-small cell lung cancer (NSCLC) ranks the first in incidence and mortality among malignant tumors in China. Molecular targeted therapies such as gefitinib, an oral inhibitor of the epidermal growth factor receptor tyrosine kinase, have shown significant benefits in patients with advanced NSCLC. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Tianyao, Huang, Jiali, Xie, Fei, Gu, Jingyao, Cheng, Zhixiang, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828391/
https://www.ncbi.nlm.nih.gov/pubmed/35462475
http://dx.doi.org/10.3724/abbs.2022023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828391/
https://www.ncbi.nlm.nih.gov/pubmed/35462475
http://dx.doi.org/10.3724/abbs.2022023

Ejemplares similares